Nilanjan Ghosh

21PUBLICATIONS
136CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCardiology (incl. cardiovascular diseases)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 17, 2026
Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

|Jun 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Apr 21, 2026
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

|Jan 06, 2026
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.

Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

Pageof 4

Frequent Collaborators

7 joint publications

Natalie S Grover

5 joint publications

Michael Wang

5 joint publications

Reem Karmali

4 joint publications

Yucai Wang